Liu YR - Search Results

1

Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.

Yang HY, Ma D, Liu YR, Hu X, Zhang J, Wang ZH, Di GH, Hu XC, Shao ZM. Yang HY, et al. Among authors: liu yr. Sci Rep. 2017 Apr 25;7(1):1134. doi: 10.1038/s41598-017-00663-1. Sci Rep. 2017. PMID: 28442763 Free PMC article.

2

Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.

Liu YR, Jiang YZ, Yu KD, Shao ZM. Liu YR, et al. Ann Surg Oncol. 2015 Apr;22(4):1102-10. doi: 10.1245/s10434-014-4108-5. Epub 2014 Sep 24. Ann Surg Oncol. 2015. PMID: 25249260

3

Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status.

Jiang HS, Kuang XY, Sun WL, Xu Y, Zheng YZ, Liu YR, Lang GT, Qiao F, Hu X, Shao ZM. Jiang HS, et al. Among authors: liu yr. Oncotarget. 2016 Jul 5;7(27):41285-41293. doi: 10.18632/oncotarget.9778. Oncotarget. 2016. PMID: 27285752 Free PMC article.

4

Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study.

Gong Y, Liu YR, Ji P, Hu X, Shao ZM. Gong Y, et al. Among authors: liu yr. Sci Rep. 2017 Mar 27;7:45411. doi: 10.1038/srep45411. Sci Rep. 2017. PMID: 28345619 Free PMC article.

5

Elevated miR-301a expression indicates a poor prognosis for breast cancer patients.

Zheng JZ, Huang YN, Yao L, Liu YR, Liu S, Hu X, Liu ZB, Shao ZM. Zheng JZ, et al. Among authors: liu s, liu zb, liu yr. Sci Rep. 2018 Feb 2;8(1):2225. doi: 10.1038/s41598-018-20680-y. Sci Rep. 2018. PMID: 29396508 Free PMC article.

6

Epidemiology and survival outcomes of mucinous adenocarcinomas: A SEER population-based study.

Xie GD, Liu YR, Jiang YZ, Shao ZM. Xie GD, et al. Among authors: liu yr. Sci Rep. 2018 Apr 17;8(1):6117. doi: 10.1038/s41598-018-24540-7. Sci Rep. 2018. PMID: 29666453 Free PMC article.

7

Author Correction: Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.

Yang HY, Ma D, Liu YR, Hu X, Zhang J, Wang ZH, Di GH, Hu XC, Shao ZM. Yang HY, et al. Among authors: liu yr. Sci Rep. 2018 Oct 12;8(1):15333. doi: 10.1038/s41598-018-32881-6. Sci Rep. 2018. PMID: 30310090 Free PMC article.

8

Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance.

Sun W, Xu X, Jiang Y, Jin X, Zhou P, Liu Y, Guo Y, Ma D, Zuo W, Huang S, He X, Shao Z. Sun W, et al. Int J Cancer. 2019 Aug 1;145(3):842-856. doi: 10.1002/ijc.32185. Epub 2019 Feb 19. Int J Cancer. 2019. PMID: 30720865

9

MicroRNA-493 is a prognostic factor in triple-negative breast cancer.

Yao L, Liu Y, Cao Z, Li J, Huang Y, Hu X, Shao Z. Yao L, et al. Cancer Sci. 2018 Jul;109(7):2294-2301. doi: 10.1111/cas.13644. Epub 2018 Jun 27. Cancer Sci. 2018. PMID: 29777630 Free PMC article.

10

Immediate postmastectomy breast reconstruction showed limited advantage in patient survival after stratifying by family income.

Jiang YZ, Liu YR, Yu KD, Zuo WJ, Shao ZM. Jiang YZ, et al. Among authors: liu yr. PLoS One. 2013 Dec 12;8(12):e82807. doi: 10.1371/journal.pone.0082807. eCollection 2013. PLoS One. 2013. PMID: 24349366 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

760 results

Search Page

Filters